全文获取类型
收费全文 | 5279篇 |
免费 | 431篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 222篇 |
妇产科学 | 216篇 |
基础医学 | 722篇 |
口腔科学 | 139篇 |
临床医学 | 506篇 |
内科学 | 1060篇 |
皮肤病学 | 77篇 |
神经病学 | 269篇 |
特种医学 | 348篇 |
外国民族医学 | 1篇 |
外科学 | 812篇 |
综合类 | 60篇 |
一般理论 | 2篇 |
预防医学 | 374篇 |
眼科学 | 60篇 |
药学 | 359篇 |
中国医学 | 3篇 |
肿瘤学 | 482篇 |
出版年
2021年 | 50篇 |
2020年 | 41篇 |
2019年 | 46篇 |
2018年 | 93篇 |
2017年 | 93篇 |
2016年 | 96篇 |
2015年 | 131篇 |
2014年 | 161篇 |
2013年 | 208篇 |
2012年 | 221篇 |
2011年 | 219篇 |
2010年 | 191篇 |
2009年 | 175篇 |
2008年 | 162篇 |
2007年 | 212篇 |
2006年 | 182篇 |
2005年 | 212篇 |
2004年 | 197篇 |
2003年 | 174篇 |
2002年 | 162篇 |
2001年 | 155篇 |
2000年 | 142篇 |
1999年 | 132篇 |
1998年 | 149篇 |
1997年 | 125篇 |
1996年 | 140篇 |
1995年 | 107篇 |
1994年 | 103篇 |
1993年 | 72篇 |
1992年 | 107篇 |
1991年 | 99篇 |
1990年 | 95篇 |
1989年 | 117篇 |
1988年 | 113篇 |
1987年 | 98篇 |
1986年 | 88篇 |
1985年 | 103篇 |
1984年 | 46篇 |
1983年 | 41篇 |
1982年 | 45篇 |
1981年 | 40篇 |
1980年 | 34篇 |
1979年 | 38篇 |
1978年 | 38篇 |
1977年 | 40篇 |
1976年 | 32篇 |
1975年 | 38篇 |
1973年 | 47篇 |
1970年 | 28篇 |
1966年 | 29篇 |
排序方式: 共有5740条查询结果,搜索用时 0 毫秒
1.
2.
3.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
4.
5.
The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology 总被引:6,自引:0,他引:6
In order to test its potential application to surgical neuropathology, the monoclonal antibody Ki-67 was used to demonstrate immunohistochemically the proliferating cells in 40 neoplasms of the nervous system. The antibody, which reacts with a nuclear protein expressed in the G1, G2, S, and M phases of the cell cycle, was demonstrated in frozen sections of all lesions. The highest incidence of stained nuclei was found in a metastatic carcinoma (57%). The percentage of stained cells in gliomas was in general agreement with the histologic grade and known biologic behavior of the lesions, ranging from 0.6% in a pilocytic astrocytoma to 12.4% in a glioblastoma multiforme. In the fibrillary astrocytic neoplasms of low cellularity, there were good correlations between the percentages of stained cells and the degrees of nuclear pleomorphism and chromatin density. In meningiomas, schwannomas, and a cerebellar hemangioblastoma, the fractions of labeled nuclei were less than 1%. The percentage of stained cells in pituitary adenomas showed considerable variation among the four cases (0.2-1.5%), the biologic significance of which is unknown. In four of the above cases, Ki-67 staining was performed on air-dried squash preparations with excellent visualization of immunoreactive nuclei. In one case, a hemangioblastoma, no stained nuclei were seen. The results confirm that Ki-67 staining is technically suitable as a diagnostic method, with good correlations between frozen sections and smear preparations. Determination of the replicating cell fraction could become an important additional criterion to predict the biologic behavior of nervous system neoplasms. 相似文献
6.
7.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
8.
9.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
10.